Bond debutant Formycon reports success in patient recruitment for blockbuster competitor

Rheinmetall, Renk, and Hensoldt have dominated the arms boom of recent years, but these stocks are now fundamentally hopelessly overvalued. P/E ratios exceed 60, price-to-sales ratios exceed 4, and this in a politically fragile environment with shaky fiscal discipline. This can be expensive for late-entering investors. But there are alternatives that have so far flown under the radar: solidly valued, operationally strong, and with catch-up potential. In our free report, we show you which three arms companies still have potential and how you can profit from the second wave of the turning point without getting burned by overheated high-flyers. Get the latest report! Don't miss out on which stocks are particularly likely to benefit from the global arms buildup and download the free PDF now.

This exclusive offer is only valid for a limited time! So download it now!